We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Abbott Laboratories | NYSE:ABT | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.46 | -0.43% | 105.46 | 106.64 | 105.475 | 106.40 | 3,598,121 | 01:00:00 |
From May 2019 to May 2024
By Tess Stynes
Abbott Laboratories filed to offer nearly a third of its stake in Mylan NV that it got from the recent sale of a portion of its generic-drugs business to the Netherlands-based drug maker.
The companies in July said Mylan would buy Abbott's drug portfolio in developed overseas markets, in a $5.3 billion deal that would allow Mylan to benefit from a lower tax rate by organizing the new company in the Netherlands. Under a revised deal, Abbott received a stake of about 22% in the new Mylan.
The stock sale unveiled Monday includes 35 million shares, or about 31.8% of the 110 million shares that Abbott received under the deal.
Mylan isn't selling any shares in the offering and won't receive any of the proceeds.
Write to Tess Stynes at tess.stynes@wsj.com
Access Investor Kit for Abbott Laboratories
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US0028241000
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Abbott Laboratories Chart |
1 Month Abbott Laboratories Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
